ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.

Zhejiang AngLiKang Pharmaceutical CO.,LTD.

002940

CNE100003GC2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 07/07/2024 BST			5-day change	1st Jan Change
13.61 ^CNY	-4.69%		-6.01%	-37.31%

07-02	Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	CI
07-02	Anglikang Pharmaceutical's Two Drugs Get Marketing Nod	MT

Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on January 23, 2021.

January 05, 2022 at 07:34 pm

From October 1, 2021 to December 31, 2021, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 2,060,000 shares, representing 2.14% for CNY 63.33 million under the buyback announced on January 23, 2021.

Latest news about Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	07-02	CI
Anglikang Pharmaceutical's Two Drugs Get Marketing Nod	07-02	MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on Share A for the Year 2023, Payable on June 17, 2024	06-07	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	04-01	CI
Anglikang Pharmaceutical Signs Licensing Deal for Affinity Biomedical's Tumor Drug	02-06	MT
Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets	01-29	MT
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	01-02	CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	10/10/23	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. announces an Equity Buyback for CNY 60 million worth of its shares.	30/08/23	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. authorizes a Buyback Plan.	29/08/23	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Anglikang Pharmaceutical's Unit Gets Veterinary, GMP Certificates	17/08/23	MT
Anglikang Pharmaceutical Registers Metabolism Disorder Drug in China	27/06/23	MT
Anglikang Pharma Obtains Nod to Market Sevoflurane Active Pharma Ingredient in China	16/06/23	MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on May 19, 2023	12/05/23	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Approves Final Cash Dividend for 2022	24/04/23	CI
Anglikang Pharma Signs Five-Year Purchase Agreement With European Firm	06/04/23	MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for 2022	02/04/23	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Anglikang Pharma’s Drug to Lower Hypertension Fails to Make It on China’s Drug Procurement List	30/03/23	MT
Chinese Shares End Mixed; Anglikang Pharma Slides 8% on 191 Million Yuan M&A Plan	24/03/23	MT
Zhejiang Anglikang Pharma to Boost Stake in Local Biopharma Firm to 62% For 191 Million Yuan	24/03/23	MT
Zhejiang AngLiKang Pharmaceutical CO.,LTD. completed the acquisition of an additional 38.22% stake in Hunan Kerey Pharmaceutical Co., Ltd. from Gan Hongxing, Hu Aiguo, Yang Xiangxin and Xie Laibin.	21/03/23	CI

Chart Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Duration

Period

Chart Zhejiang AngLiKang Pharmaceutical CO.,LTD.

More charts

Company Profile

Zhejiang AngLiKang Pharmaceutical CO.,LTD. is a China-based company principally engaged in the research, development, production and sales of chemical raw materials and preparations. The Company's products mainly include cephalosporin and penicillin series, anti-hypertension series, digestive system series, kidney disease series and others.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.	-37.31%	392M
ELI LILLY AND COMPANY	+57.54%	823B
JOHNSON & JOHNSON	-6.90%	353B
MERCK & CO., INC.	+15.36%	320B
ABBVIE INC.	+7.33%	295B
ASTRAZENECA PLC	+13.62%	239B
NOVARTIS AG	+14.55%	220B
ROCHE HOLDING AG	-0.33%	219B
AMGEN INC.	+8.22%	167B
PFIZER, INC.	-2.87%	159B